Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed) | PAR 24 198

FAQs: NIH PAR-24-198 (R01) - Mechanistic Research on ARIA in Anti-Amyloid Beta Immunotherapy

What is NIH PAR-24-198?

PAR-24-198 is a National Institutes of Health (NIH) funding opportunity announcement for an R01 research project grant focused on understanding and reducing amyloid-related imaging abnormalities (ARIA) associated with passive anti-amyloid beta immunotherapy used in the Alzheimer disease treatment space.

What is the main goal of this funding opportunity?

The main goal is to build a deeper, mechanistic understanding of how passive anti-amyloid beta antibodies affect brain blood vessels and the blood-brain barrier (BBB) when they interact with amyloid in or around cerebral vessels, and to identify actionable targets and protective strategies that could reduce ARIA risk.

Is this opportunity meant to support clinical trials?

No. The announcement is explicitly labeled "Clinical Trial Not Allowed." The work should be preclinical and/or mechanistic rather than interventional studies in humans that meet NIH's definition of a clinical trial.

What type of grant mechanism is PAR-24-198?

This opportunity uses the NIH R01 mechanism, which typically supports substantial, hypothesis-driven research projects designed to generate rigorous mechanistic insight.

What problem is the research trying to address?

The research is intended to address ARIA, which is framed here as an adverse vascular and BBB-related response that can occur after passive anti-amyloid beta immunotherapy. The focus is on explaining the cellular and molecular responses that drive these imaging abnormalities.

What is ARIA in the context of this opportunity?

ARIA refers to amyloid-related imaging abnormalities observed on brain imaging, including findings consistent with edema or microhemorrhages. In this opportunity, ARIA is treated as a sign of underlying vessel and BBB dysfunction triggered by immunotherapy-related interactions with amyloid in or near cerebral vessels.

What scientific areas or systems are emphasized?

The opportunity emphasizes cerebrovascular biology and BBB stability, including the cells and molecular pathways that make up the neurovascular unit and govern vascular integrity under amyloid-targeting antibody exposure.

What kinds of research questions are encouraged?

Applications are expected to dig into mechanisms behind vessel and BBB dysfunction in this setting, such as how antibody-mediated amyloid clearance affects vascular integrity, inflammation, immune cell interactions, endothelial function, perivascular drainage, and other processes that could contribute to edema or microhemorrhages seen on imaging.

What is the intended outcome of funded projects?

The intended outcome is a clearer map of the cellular and molecular pathways driving ARIA risk, with the goal of identifying targets and developing protective strategies that stabilize the BBB and cerebrovascular system during amyloid-targeting therapies.

Does the opportunity prioritize discovery or product development?

Based on the description provided, the emphasis is on discovery and target identification: mechanistic understanding of BBB and vessel biology that can inform future protective approaches and safer therapeutic interventions.

What is the award ceiling listed for this opportunity?

The listed award ceiling is $500,000.

When is the closing date for PAR-24-198?

The original closing date provided is 2024-11-05.

How many awards will NIH make under this opportunity?

The expected number of awards is not specified in the provided information.

What funding category does this opportunity fall under?

It falls under the broader health research funding activity category and is an NIH-sponsored discretionary grant.

Which CFDA numbers are associated with this opportunity?

The opportunity is associated with CFDA numbers 93.853 and 93.866.

Who is eligible to apply?

Eligibility is broad and includes many U.S.-based organizations and governmental entities. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments that are federally recognized; Native American tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in that category description); for-profit organizations other than small businesses; and small businesses.

Are specific institution types called out as eligible?

Yes. The announcement highlights eligibility for categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.

Can a non-U.S. (foreign) organization apply directly?

No. Non-domestic (non-U.S.) entities are not eligible to apply.

Can a U.S. organization include a non-U.S. project site or non-domestic component?

No. Non-domestic components of U.S. organizations are not eligible to apply under this opportunity.

Are any international elements allowed at all?

Yes. "Foreign components," as defined by the NIH Grants Policy Statement, are allowed. This generally means a U.S. applicant organization may include certain well-justified international elements within the overall project, provided NIH policy requirements are met.

What is the central scientific theme behind the opportunity?

The central theme is that ARIA reflects adverse cerebrovascular and BBB-related responses to passive anti-amyloid beta immunotherapy, and that these responses are likely governed by specific molecular pathways in cells of the neurovascular unit.

What kinds of biological mechanisms are within scope based on the description?

Mechanisms within scope include molecular and cellular responses affecting vascular integrity and BBB function, including inflammation, immune cell interactions, endothelial function, and perivascular drainage changes linked to antibody-mediated amyloid clearance and vascular amyloid interactions.

What is the practical impact NIH is trying to enable with this research?

The practical impact is to enable safer beta-amyloid-targeting therapies by identifying protective targets or strategies that reduce ARIA risk and help keep the BBB and cerebrovascular system more stable during treatment.

Is the focus limited to imaging findings themselves?

No. While ARIA is defined by imaging abnormalities, the emphasis is on understanding the underlying BBB and cerebrovascular biology and the cellular and molecular pathways that produce those imaging findings.

Does the opportunity focus on passive immunotherapy specifically?

Yes. The description specifically targets ARIA that can occur after passive anti-amyloid beta immunotherapy, with a focus on what happens when anti-amyloid beta antibodies interact with amyloid in or around cerebral vessels.